Emcure Pharmaceuticals Launches Poviztra for Weight Management in India
Filing Summary
Emcure Pharmaceuticals Ltd. has announced the launch of Poviztra®, a semaglutide injection for weight management, in India. This marks Emcure as the first Indian company to distribute and commercialize this product, which is available in a once-weekly pen device across five strengths. The starting price is ₹8790 per month. Poviztra® is indicated for adults with obesity or overweight conditions and is supported by extensive clinical trials. The launch aims to address the obesity crisis in India, where millions are affected by obesity-related health issues.
Emcure Pharmaceuticals Ltd. has announced the commercial launch of Poviztra®, a semaglutide injection for weight management, across India. This launch positions Emcure as the first Indian company to exclusively distribute and commercialize Poviztra®, a second brand of Novo Nordisk’s semaglutide injection. The product is available in a once-weekly pen device with five strengths: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and a maintenance dose of 2.4 mg.
The starting price for Poviztra® is ₹8790 per month, covering four weekly doses. The pen device is designed to offer simple and precise dosing. The semaglutide injection is backed by clinical evidence from the STEP and SELECT clinical trial programs. Globally, the molecule has nearly a decade of market presence, with 38 million patient-years of exposure, supported by a strong safety and efficacy profile.
Poviztra® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with a body mass index (BMI) of 30 kg/m2 or greater, or 27 kg/m2 or greater with at least one weight-related comorbid condition. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. In clinical trials, the semaglutide formulation achieved weight loss of more than 20% in many patients.
India is currently facing a significant obesity crisis, with approximately 254 million people living with generalized obesity and an additional 351 million with abdominal obesity. The introduction of Poviztra® aims to expand access to scientifically validated weight-management solutions. Emcure plans to leverage its distribution capabilities and pan-India reach to ensure that more patients can benefit from advanced therapies like semaglutide.
The launch of Poviztra® is part of Emcure’s ongoing efforts to address the growing burden of overweight and obesity in India. Obesity is linked to over 230 health complications, including cardiovascular disease, fatty liver, knee osteoarthritis, polycystic ovary syndrome, kidney disease, and Alzheimer’s disease.
Emcure Pharmaceuticals Ltd. is a leading Indian pharmaceutical company headquartered in Pune. The company is engaged in developing, manufacturing, and globally marketing a broad range of pharmaceutical products. Known for its commitment to innovation, quality, and patient-centricity, Emcure is an R&D-driven company that develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Established in 1981, Emcure is ranked as the 13th largest pharma company in India in terms of domestic sales for MAT October 2025 and is present in over 70 countries globally, including Europe and Canada.